TCF Stock Overview
A clinical stage therapeutics company, engages in the development of therapeutics for oncology and behavioral brain disorders.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Theracryf Plc Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | UK£0.0075 |
52 Week High | UK£0.038 |
52 Week Low | UK£0.006 |
Beta | 1.46 |
1 Month Change | 0% |
3 Month Change | -26.83% |
1 Year Change | -79.45% |
3 Year Change | -91.23% |
5 Year Change | -96.30% |
Change since IPO | -97.86% |
Recent News & Updates
Recent updates
Here's Why We're Not Too Worried About Evgen Pharma's (LON:EVG) Cash Burn Situation
Oct 11We're Hopeful That Evgen Pharma (LON:EVG) Will Use Its Cash Wisely
Nov 24Here's Why We're Not Too Worried About Evgen Pharma's (LON:EVG) Cash Burn Situation
Aug 06Is Evgen Pharma (LON:EVG) In A Good Position To Deliver On Growth Plans?
Apr 09We're Keeping An Eye On Evgen Pharma's (LON:EVG) Cash Burn Rate
Dec 25Shareholder Returns
TCF | GB Biotechs | GB Market | |
---|---|---|---|
7D | 7.1% | 1.4% | -0.3% |
1Y | -79.5% | -21.2% | 5.5% |
Return vs Industry: TCF underperformed the UK Biotechs industry which returned -21.2% over the past year.
Return vs Market: TCF underperformed the UK Market which returned 5.5% over the past year.
Price Volatility
TCF volatility | |
---|---|
TCF Average Weekly Movement | 7.2% |
Biotechs Industry Average Movement | 6.6% |
Market Average Movement | 4.9% |
10% most volatile stocks in GB Market | 11.2% |
10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: TCF's share price has been volatile over the past 3 months.
Volatility Over Time: TCF's weekly volatility (7%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2014 | 10 | Huw Jones | theracryf.com |
Theracryf Plc, a clinical stage therapeutics company, engages in the development of therapeutics for oncology and behavioral brain disorders. The company’s lead product is SFX-01 that is in Phase II clinical trials for the treatment of metastatic breast cancer; and in Phase Ib/IIa clinical trials for the treatment of glioblastoma and Phase I clinical trials for the treatment of neurodevelopmental disorders, as well as in preclinical stage for the treatment of rhabdomyosarcoma. In addition, it engages in the development of orexin 1 antagonist, which is in late preclinical stage targeting addictive behaviors; orexin 1 antagonist that is in late preclinical stage for the treatment of anxiety; and molecule DAT inhibitor, which is in late preclinical stage targeting fatigue and narcolepsy.
Theracryf Plc Fundamentals Summary
TCF fundamental statistics | |
---|---|
Market cap | UK£3.21m |
Earnings (TTM) | -UK£3.14m |
Revenue (TTM) | UK£396.00k |
8.1x
P/S Ratio-1.0x
P/E RatioIs TCF overvalued?
See Fair Value and valuation analysisEarnings & Revenue
TCF income statement (TTM) | |
---|---|
Revenue | UK£396.00k |
Cost of Revenue | UK£3.83m |
Gross Profit | -UK£3.43m |
Other Expenses | -UK£292.00k |
Earnings | -UK£3.14m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.0073 |
Gross Margin | -865.91% |
Net Profit Margin | -792.17% |
Debt/Equity Ratio | 0% |
How did TCF perform over the long term?
See historical performance and comparison